NCT06968195 2026-04-15
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Roswell Park Cancer Institute
Phase 1 Suspended
Clinical Trials
12 trialsNCT05435014 2026-04-14
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
T-ACE Medical Co., Ltd
Phase 1/2 Suspended
NCT04955808 2026-04-13
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
National Cancer Institute (NCI)
Suspended
NCT05546879 2026-02-10
Liver-NET1
University Hospital, Grenoble
Phase 1 Suspended
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT05620771 2025-10-20
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
Phase 2 Suspended
NCT05603572 2025-06-05
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Primocure Pharma
Phase 1/2 Suspended
NCT04268888 2025-02-26
TACE-3
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2/3 Suspended
NCT02935478 2025-02-06
Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation
St. Louis University
Phase NA Suspended
NCT04506983 2022-02-14
GPC3-CAR-T Cells for the Hepatocellular Carcinoma
Beijing Tsinghua Chang Gung Hospital
Phase 1 Suspended
NCT03990974 2020-03-25
HCC
Sun Yat-sen University
Phase 3 Suspended
NCT02026362 2017-10-18
HCC DC CTL
HRYZ Biotech Co.
Phase 1/2 Suspended